BackgroundAlthough generative artificial intelligence offers substantial potential benefits in healthcare, negative attitudes and elevated anxiety among nurses may hinder its effective integration into clinical practice. Evidence regarding the psychological impact of generative artificial intelligence on nurses remains limited.ObjectiveThis study examined the relationships among sociodemographic characteristics, anxiety, and attitudes toward generative artificial intelligence among nurses.MethodsA cross-sectional correlational design was employed. Data were collected from 312 hospital nurses using online questionnaires assessing sociodemographic characteristics, attitudes toward artificial intelligence, and artificial intelligence-related anxiety. Data were analyzed using IBM Statistical Package for the Social Sciences (SPSS) Statistics software version 28.ResultsHigher levels of artificial intelligence-related anxiety were associated with less favorable attitudes toward artificial intelligence. Sociodemographic characteristics and anxiety scores collectively explained 49.4% of the total variance in attitudes toward artificial intelligence. Gender, experience with artificial intelligence, use of artificial intelligence in nursing care, awareness of artificial intelligence applications in healthcare, hours spent on the internet, age, and professional experience accounted for 24.7% of the variance in negative attitudes toward generative artificial intelligence.ConclusionAnxiety and experiential factors play a central role in shaping nurses’ attitudes toward generative artificial intelligence. Increasing nurses’ exposure to and awareness of artificial intelligence in nursing practice may reduce anxiety and support its acceptance and appropriate use.
Improving metagenome binning by integrating intrinsic features and taxonomy
Nature Biotechnology, Published online: 27 April 2026; doi:10.1038/s41587-026-03098-0
TaxVAMB combines sequence features with taxonomic information for improved metagenome binning.
Ten lessons from a decade of scientific translation at the Crick
Nature Medicine, Published online: 27 April 2026; doi:10.1038/s41591-026-04355-0
Ten lessons from a decade of scientific translation at the Crick
The TARGET guideline for reporting observational studies of interventions
Nature Medicine, Published online: 27 April 2026; doi:10.1038/s41591-026-04358-x
The TARGET guideline for reporting observational studies of interventions
The arrival of digital twins and in silico trials in drug development
Nature Medicine, Published online: 27 April 2026; doi:10.1038/s41591-026-04344-3
The regulatory landscape for drug evaluation is shifting. For digital twins and in silico trials to become reliable evidence for drug approvals, these digital tools will require input from regulators and the public sector to ensure safe and responsible adoption.
The All of Us Research Program’s wearables dataset
Nature Medicine, Published online: 27 April 2026; doi:10.1038/s41591-026-04352-3
The authors present the All of Us Research Program dataset, containing Fitbit data from 59,000 participants spanning 14 years, 39 million steps and 31 million sleep observations.
Brain motion is driven by mechanical coupling with the abdomen
Nature Neuroscience, Published online: 27 April 2026; doi:10.1038/s41593-026-02279-z
Using two-photon imaging in mice, Garborg et al. show that brain movement within the skull is driven by abdominal muscle contractions through mechanical coupling with the abdomen. Simulations suggest that this brain motion could contribute to cerebrospinal fluid circulation.
Cheese3D enables sensitive detection and analysis of whole-face movement in mice
Nature Neuroscience, Published online: 27 April 2026; doi:10.1038/s41593-026-02262-8
The authors developed Cheese3D, a hardware–software framework for precise and sensitive measurement of whole-face movements in mice that enables quantitative inference of neural and physiological processes.
STAT+: Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial
Intellia Therapeutics said Monday that a single dose of its gene editing treatment dramatically reduced swelling attacks in patients with a rare genetic disorder in a Phase 3 trial, setting up a potential approval.
The therapy, known as lonvo-z, would be the second approved CRISPR-based medicine, after Vertex Pharmaceutical’s sickle cell treatment Casgevy. Intellia has already initiated a rolling submission with the agency. It would be the first in vivo treatment, meaning it edits patients’ DNA directly in the body.
In the 80-patient study, volunteers with hereditary angioedema (HAE) who received lonvo-z saw their attack rates drop 87%, relative to placebo. Just over 60% were entirely attack-free over the period, compared to 11% for the placebo patients.
STAT+: Veradermics’ hair loss drug succeeds in late-stage trial
An oral medicine for hair loss successfully spurred hair growth in a late-stage trial, startup Veradermics announced Monday.
Veradermics assessed the pill in two ways: by how many hairs grew within a square centimeter of the scalp, on average, and by how satisfied participants were with the results. Over the course of six months, men who took the drug, known as VDPHL01, either once or twice daily had between 30 and 33 more hairs per square centimeter of scalp. Men in the placebo group grew approximately seven additional hairs.
Between 79% and 86% of men taking VDPHL01 said they saw improvement, along with between 72% and 84% of the clinical trial investigators — results that pleased Reid Waldman, a dermatologist turned Veradermics’ chief executive.